STERIS plc (STE) Earnings Call Transcripts

STERIS plc's Latest Earnings Call - September 15, 2026

In the fiscal quarter ending September 15, 2026, STERIS plc reported solid performance with a revenue of $4 billion, reflecting mid-single-digit organic growth driven by a strong recurring revenue model. Earnings per share (EPS) were reported at $1.25, slightly above expectations, signaling resilience in the healthcare sector despite economic pressures. Management maintained guidance for mid- to high single-digit revenue growth and double-digit bottom line growth, emphasizing confidence in their business model and market share expansion, particularly in Europe.

Reported metrics

Guidance from management

Management maintained guidance for mid- to high single-digit revenue growth and double-digit EPS growth, emphasizing confidence in their recurring revenue model and market share expansion.

What management said

I think a real focus for us is geographies, either through channel acquisition or in-country opportunities in the space that we're in, in terms of sterilization disinfection. Some of those are still out there. And we continue to look at them and things like that. It's hard to say when and if anything will happen. And so really, the focus is us taking over geographic expansion organically. If something presents itself...

Our stated goals are 7% and 11%, 7% on top, 11% on the bottom. And maybe there's some tuck-in M&A involved in that, but that's pretty much organic. And we believe that we're in a position with the business that we can deliver that provided that procedure volumes stay somewhere in that 2% to 4% range. We think that bodes well for us in our ability to execute. So you can compound that over 5 years. I think that we'll b...

What analysts pressed on

Analysts expressed concerns regarding the sustainability of growth in the healthcare segment as the business scales. There were questions about the potential impacts of economic pressures on capital spending and procedure volumes moving forward.

Main topics on the call

• Recurring Revenue Strength — Management highlighted that 80% of STERIS's revenue now comes from recurring sources, which has been a significant shift from a decade ago. CEO Daniel Carestio stated, "When you have 80% of your revenue that's largely pr...
• Procedure Volume Growth — Despite economic pressures, STERIS reported modest growth in procedure volumes, particularly in endoscopy, which saw increases of 7% to 8.5%. Carestio noted, "We continue to see some modest level of procedure volume grow...
• Investment in Manufacturing — STERIS announced a $600 million investment in a new manufacturing center in North Carolina, which is expected to enhance capacity and efficiency. Carestio described it as "the most low-risk investment you can make," supp...
• Market Share Expansion — Management expressed confidence in their ability to gain market share, particularly in Europe, where they have a smaller presence. Carestio stated, "There's still a lot of market share out there to be had, both in North ...

Read the full STERIS plc transcript (September 15, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 36 STERIS plc earnings call transcripts on record, spanning February 11, 2020 to September 15, 2026. Based on this history, STERIS plc reports quarterly. The most recent call on file is dated September 15, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

STE

Exchange

NYSE

Country

US

Sector

Health Care

Industry

Health Care Equipment and Supplies

Calls on record

36

First call

February 11, 2020

Most recent

September 15, 2026

Reporting cadence

quarterly